Trials / Completed
CompletedNCT00834080
ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals
Open-Label Study of the Safety and Tolerability of VIVITROL Administered to Health Care Professionals Participating in an Extended Outpatient Treatment Program for Opioid Dependence
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of Medisorb® naltrexone (VIVITROL®) when administered over a period of 24 months to health care professionals who have a history of opioid dependence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Medisorb naltrexone 380 mg | Intramuscular (IM) injection administered once every 4 weeks for up to 2 years |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2012-05-01
- Completion
- 2012-05-01
- First posted
- 2009-02-03
- Last updated
- 2018-12-11
- Results posted
- 2013-07-29
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00834080. Inclusion in this directory is not an endorsement.